Biotechnology
Filter News
Found 21,119 articles
-
BioInvent strengthens Investor Relations - Nov 27, 2020
11/27/2020
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent covering external communications and investor relations.
-
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
11/27/2020
The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations
-
Thankful for Biopharma Breakthroughs
11/26/2020
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year. -
Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis
11/26/2020
Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
-
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
11/26/2020
Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol outperforms the other listing drugs for the treatment of relapsed AML patients in its Phase 2 clinical study conducted in Russia.
-
Kane Biotech Announces Third Quarter 2020 Financial Results
11/26/2020
Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced their third quarter 2020 financial results.
-
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda
11/26/2020
Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited.
-
BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10
11/26/2020
Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis.
-
There has been a high level of movement in COVID-19 vaccine news this week, with Pfizer and BioNTech, Moderna, and AstraZeneca and the University of Oxford all having positive clinical trial announcements. Here’s some follow-up news.
-
Biopharma Money on the Move: November 18-24
11/25/2020
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.
-
In the cleanroom environment specifically, the benefits of automation are more than meets the microscope.
-
Equillium Provides Itolizumab COVID-19 Program Update Analyst Day scheduled for December 4, 2020
11/25/2020
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time.
-
Novavax to Participate in Upcoming Conferences - Nov 25, 2020
11/25/2020
Novavax Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it will participate in two upcoming investor conferences.
-
PostEra and NeuroLucent collaborate on identifying small-molecule therapeutics for Alzheimer's disease
11/25/2020
PostEra, a biotechnology company offering medicinal chemistry powered by machine learning, today announced a collaboration with NeuroLucent, a Chicago-based company focused on developing novel treatments for Alzheimer's disease and other dementias.
-
Genus plc Provides Update on Fiscal 2021 Financial Performance
11/25/2020
Global biotechnology leader in animal genetics reports continued strong performance for the period from July 1, 2020 through November 24, 2020
-
Genentech’s influenza treatment Xofluza® (baloxavir marboxil) has been granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the agency.
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
-
bluebird bio Announces Live Webcast to Review Clinical Data Presented at the 62nd American Society of Hematology (ASH) Annual Meeting
11/24/2020
bluebird bio, Inc. announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition.